Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy SIR, Since 2000, the UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC) has recruited idiopathic inflammatory myopathy (IIM) cases across the UK. In this brief report, we summarize the clinical, serological and HLA Class II status of non-Caucasian IIM cases, to ascertain whether differences are observed among UK IIM ethnic populations.
After stratification by gender, this observation was only significantly lower in non-Caucasian females [non-Caucasians females, 33 years (27, 41) vs Caucasian females, 49 years (38, 60), P ¼ 0.0001]. No significant difference for age of onset was noted between African/Afro-Caribbean or Asian cases.
CAM was not detected in the non-Caucasian cohort, but was present in 6% of the Caucasian IIM cohort, and in 15% of the DM cases [4] . With respect to ILD, there were eight (29%) nonCaucasian IIM cases and six of seven (86%) anti-synthetase antibody-positive cases. Although a higher frequency of ILD was observed in African/Afro-Caribbean (35%) compared with Asian (18%) cases, due to the small sample size this was not statistically significant (P ¼ 0.24). This difference was not attributable to differences in anti-synthetase antibody frequency. In comparison, the overall frequency of ILD in the Caucasian cohort was 20%, and 44% in anti-synthetase positive cases. Within the nonCaucasian cohort, only PM cases possessed anti-Jo-1 antibody (n ¼ 3) and anti-Mi-2 antibody (n ¼ 2). Two additional DM cases (PL-12, OJ) and none of the overlap cases possessed antisynthetase antibodies other than anti-Jo-1. The only myositisspecific antibodies recorded in the Asian cases were two cases with anti-Jo-1 antibodies. Three PM cases possessed multiple antibodies (one with Jo-1 and U1-RNP; one with Mi-2 and U1-RNP; one with EJ, Ku and U1-RNP). No cases with anti-SRP, -KS or -155/140 antibodies were noted.
All anti-PM-Scl, anti-Mi-2, two of three anti-Jo-1 and the single anti-PL-12 antibody-positive case possessed a copy of HLA-DRB1*03. Six of 10 anti-U1-RNP antibody-positive patients possessed a copy of HLA-DR2 (DRB1*15/16). None of the anti-U1-RNP antibody-positive patients was HLA-DRB1*04 positive and neither of the anti-Mi-2 antibody-positive patients was HLA-DRB1*07 positive.
We have presented the first correlation of phenotype/serotype/ HLA Class II genotype in non-Caucasian UK IIM cases. Although this is a small study, it has provided a useful opportunity to compare these data with existing UK Caucasian data [2] . A lower median age of onset in non-Caucasian females has also been observed in SLE [5] . There is a high frequency of ILD in nonCaucasians possessing anti-synthetase antibody. Notably, ILD is also increased in African-American compared with Caucasian anti-topoisomerase I antibody-positive SSc cases [6] . The absence of CAM in the non-Caucasian cohort could be due to lack of statistical power. A low CAM frequency (2.7%) was noted in a recent larger study of 262 African-American IIM cases [7] .
The known HLA-DRB1*03 association in anti-PM-Scl and anti-synthetase positive cases is apparent across ethnic groups, but the U1-RNP/DRB1*04 and Mi-2/DRB1*07 associations described in UK IIM Caucasians [2] are not observed. The Mi-2/DRB1*03 association in UK African cases may relate to the Mi-2/DRB1*0302 association observed in African-Americans, where a shared amino acid sequence motif has been described between DRB1*0701 and DRB1*0302 [7] . However, an anti-RNP/DRB1*08 association described in the same US study was not observed in our data. We acknowledge that the low patient numbers in our study make it difficult to conduct a meaningful comparison.
Despite our data possessing comparatively small numbers, consistencies are observed with other published data [7] , emphasizing the importance of case stratification by ethnicity and serotype. Larger-scale analyses of non-Caucasian IIM cases may yield further useful information to investigate similarities and differences between different IIM ethnic groups. A 67-year-old woman presented a 1-month history of fever, polymyalgia and anorexia. Two weeks before admission, she visited the former hospital and subsequently received antibiotic therapies. As her symptoms continued, she was admitted to our hospital. On admission, her temperature was 38.58C. Heart rate was 80/min and blood pressure was 130/80 mmHg. Lungs were normal. Auscultation of the heart revealed a systolic murmur over the aortic area. On laboratory data, white blood cell counts were 16 400/mm 3 , with 84% neutrophils. Red blood cell count was 329 Â 10 4 /mm 3 and haemoglobin was 9.5 g/dl. Platelet count was 21.3 Â 10 4 /mm 3 . CRP was 5.2 mg/dl. ESR was 121 mm/h. Blood cultures were performed four times and were all negative. Plasma glucose was 103 mg/dl. Electrolytes, proteinogram, renal function and liver enzymes were all within the normal range. Urinalysis revealed that glucose was 100 mg/dl, proteinuria 30 mg/dl, microhaematuria 3þ [20-29 red blood cells/high-power field (HPF)]. Complements were all within the normal range. ANA was negative. RF was 38.7 IU/ml (<19). The cANCA and pANCA by ELISA were 8.9 U/ml (<3.5) and <1.3 U/ml (<9.0), respectively. Anti-SS-A antibody was positive. Other serological tests including anti-SS-B antibody, anti-ds-DNA antibody, anti-Sm antibody, anti-RNP antibody, anti-cardiolipin 2GPI antibody, LAC, hepatitis B virus antigen and hepatitis C virus antibody were all negative. Electrocardiography showed inversed T wave in III, aVF and V3-V6. Echocardiography revealed the vegetation on the aortic valve, consistent with endocarditis ( Fig. 1) , with moderate AR. Chest X-rays showed cardiomegaly and pleuritis with bilateral pleural effusion. Chest CT revealed the infiltration of the left upper lobe, the pleuritis with bilateral pleural effusion and pericardial effusion. Abdominal CT detected no remarkable findings including mass, ascites and splenomegaly.
The administration of 30 mg daily of oral prednisolone (PSL) was started. Her clinical manifestations, such as fever, polymyalgia and anorexia, were improved within 8 days. Fourteen days after the administration of steroid therapy, all laboratory data, including CRP (0.1 mg/dl), ESR (24 mm/h), cANCA (3.7 U/ml) and findings of imaging tests, including electrocardiography, X-rays and CT, were almost normalized. The dosage of PSL was tapered gradually, and finally decreased to 12.5 mg daily at discharge. Though the laboratory data concerning inflammation improved, she complained of acute onset dyspnoea and oedema at
